{ "ok": true, "cik": "914475", "ticker": "NBIX", "name": "NEUROCRINE BIOSCIENCES INC", "filings": [ { "form": "10-Q", "filed": "2026-07-31", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/914475/000091447526000037/0000914475-26-000037-index.htm" }, { "form": "8-K", "filed": "2026-07-30", "items": [ "2.02 Results of Operations and Financial Condition", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/914475/000091447526000035/0000914475-26-000035-index.htm" }, { "form": "8-K", "filed": "2026-05-28", "items": [ "5.02 Departure or Election of Directors; Appointment of Officers", "5.07 Submission of Matters to a Vote of Security Holders" ], "url": "https://www.sec.gov/Archives/edgar/data/914475/000091447526000029/0000914475-26-000029-index.htm" }, { "form": "8-K", "filed": "2026-05-18", "items": [ "1.01 Entry into a Material Definitive Agreement", "2.01 Completion of Acquisition or Disposition of Assets", "2.03 Creation of a Direct Financial Obligation", "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/914475/000119312526228013/0001193125-26-228013-index.htm" }, { "form": "10-Q", "filed": "2026-05-05", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/914475/000091447526000026/0000914475-26-000026-index.htm" }, { "form": "8-K", "filed": "2026-05-05", "items": [ "2.02 Results of Operations and Financial Condition", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/914475/000091447526000025/0000914475-26-000025-index.htm" } ], "events12m": 8, "healthWatch": { "window": "last 12 months", "since": "2025-09-27", "signals": [ { "code": "5.02", "label": "Director or officer change", "count": 2, "latest": { "filed": "2026-05-28", "url": "https://www.sec.gov/Archives/edgar/data/914475/000091447526000029/0000914475-26-000029-index.htm" } } ], "note": "Events the company itself filed with the SEC, most serious first. Shown beside the figures; they do not change the range or its receipt." }, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0000914475.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=914475" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets and no trading recommendations.", "edgar": "🫧 Edgar looked up NEUROCRINE BIOSCIENCES INC ($NBIX). Last filing: 10-Q, 2026-07-31. 8 event filings (8-K) in the past twelve months.", "auditor": { "changes": [], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2025-12-31", "revenue": 2860500000, "revenueGrowth1y": 0.21449496879378427, "revenueGrowthPerYear": 0.2603904588576058, "yearsOfData": 5, "operatingMargin": 0.2164306939346268, "operatingMarginPrior": 0.24221967477603704, "netMargin": 0.16731340674707218, "operatingCashFlow": 782700000, "capitalSpending": 34000000, "freeCashFlow": 748700000, "researchAndDevelopment": 1015700000, "researchShareOfRevenue": 0.355077783604265, "cash": 713000000, "longTermDebt": null, "longTermDebtChange": null, "revenueHistory": [ { "fiscalYearEnd": "2021-12-31", "revenue": 1133500000 }, { "fiscalYearEnd": "2022-12-31", "revenue": 1488700000 }, { "fiscalYearEnd": "2023-12-31", "revenue": 1887100000 }, { "fiscalYearEnd": "2024-12-31", "revenue": 2355300000 }, { "fiscalYearEnd": "2025-12-31", "revenue": 2860500000 } ], "totalEquity": 3253100000, "totalAssets": 4631500000, "equityRatio": 0.7023858361222066, "returnOnEquity": 0.14712120746365007, "dividendsPaid": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "earningsPerShare": 4.81, "sharesOutstanding": 102500000, "bookValuePerShare": 31.737560975609757, "revenuePerShare": 27.90731707317073, "range80": { "low": 3138262942.94064, "high": 3758624476.092963, "baseline": 3515134277.5680933, "n": 4599, "band": "b1", "bandLabel": "$1B–10B", "method": "v4.1", "credibility": 0.5, "growthYears": 4, "ownVolatility": 0.032657897755169356, "classVolatility": 0.07701947805587882, "volatility": 0.05915462063857352 }, "ifPaceHeld": { "low": 3138262942.94064, "high": 3758624476.092963 } }, "edgarette": "🔖 Exposure: revenue $2.9B (FY2025). Experience: revenue up 21.4% on the year, up 26.0% a year over 4 years; operating margin 21.6%, down from 24.2%. Soundness: equity 70.2% of assets, return on equity 14.7%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $3.1B and $3.8B next year (method v4.1: its own 4-year record of growth weighed at 50% against $1B–10B filers; on a year the method never saw, 83.4% landed inside). In a shock year the stress range is $2.9B to $4.0B. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin 21.6% against a -15.8% median; growth 21.4% against 21.4%.", "peers": { "sic": 2836, "sicDescription": "Biological Products, (No Diagnostic Substances)", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2836", "growth": [ 0.2145, 27 ], "opMargin": [ -0.1582, 31 ], "equityRatio": [ 0.5857, 31 ], "returnOnEquity": [ -0.0646, 25 ] }, "summary": "Neurocrine Biosciences (NBIX) grew revenue 21.4% in FY2025 to $2.9 billion, operating margin 21.6% against a -15.8% median for biological products, (no diagnostic substances), equity 70.2% of assets. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
NEUROCRINE BIOSCIENCES INC against its own record and its peers
Operating marginPeer median -15.8%21.6%Revenue, on the yearPeer median 21.4%21.4%Equity of assetsPeer median 58.6%70.2%Return on equityPeer median -6.5%14.7%Gold tick: the median of 25–31 peers with $50M+ revenue in biological products, (no diagnostic substances)
", "chartHorizon": null, "backtest": { "tests": 10, "hits": 6, "rate": 0.6, "method": "v4", "byYear": { "2013": [ 0, 1 ], "2014": [ 0, 1 ], "2017": [ 0, 1 ], "2019": [ 1, 1 ], "2020": [ 0, 1 ], "2021": [ 1, 1 ], "2022": [ 1, 1 ], "2023": [ 1, 1 ], "2024": [ 1, 1 ], "2025": [ 1, 1 ] }, "note": "hindsight: the same credibility-weighted range on the company's own past years. Years 2018-2023 were used to fit or tune the method, so only 2025 outcomes are fully out of sample." }, "registry": { "logged": "2026-09-27T21:32:54.648Z", "hash": "9195dc12be8163ef", "status": "open" }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "Neurocrine Biosciences (NBIX) grew revenue 21.4% in FY2025 to $2.9 billion, operating margin 21.6% against a -15.8% median for biological products, (no diagnostic substances), equity 70.2% of assets. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2025-12-31", "revenue": 2860500000, "totalDebt": null, "cash": 713000000 }, "experience": { "revenueGrowth1y": 0.21449496879378427, "revenueGrowthPerYear": 0.2603904588576058, "operatingMargin": 0.2164306939346268, "operatingMarginPrior": 0.24221967477603704, "netMargin": 0.16731340674707218, "freeCashFlow": 748700000 }, "soundness": { "equityRatio": 0.7023858361222066, "returnOnEquity": 0.14712120746365007, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 2836, "sicDescription": "Biological Products, (No Diagnostic Substances)", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2836", "growth": [ 0.2145, 27 ], "opMargin": [ -0.1582, 31 ], "equityRatio": [ 0.5857, 31 ], "returnOnEquity": [ -0.0646, 25 ] }, "credibility": { "auditedYears": 5, "weight": "reasonable", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": null }, "healthWatch": { "window": "last 12 months", "since": "2025-09-27", "signals": [ { "code": "5.02", "label": "Director or officer change", "count": 2, "latest": { "filed": "2026-05-28", "url": "https://www.sec.gov/Archives/edgar/data/914475/000091447526000029/0000914475-26-000029-index.htm" } } ], "note": "Events the company itself filed with the SEC, most serious first. Shown beside the figures; they do not change the range or its receipt." }, "range": { "low": 3138262942.94064, "high": 3758624476.092963, "baseline": 3515134277.5680933, "coverage": 0.8, "method": "v4.1", "basis": "next fiscal year revenue: baseline = revenue x (1 + mean of one-year and three-year pace); width = the company's own volatility of yearly growth, credibility-weighted against its size class (Buhlmann), scaled to the 80% target on 2023 and tested on 2024", "calibratedOn": { "companyYears": 4599, "sizeBand": "$1B–10B", "fitYears": [ 2018, 2022 ], "tuneYear": 2023, "testYear": 2024, "coverageOnTestYear": 0.8341 }, "credibility": { "weightOnOwnRecord": 0.5, "growthYears": 4, "ownVolatility": 0.032657897755169356, "classVolatility": 0.07701947805587882, "pricedVolatility": 0.05915462063857352, "k": 3 }, "stress": { "low": 2938184440.538101, "high": 4014827028.3766346, "basis": "the same range with widths set to hold 80% across 2018-2023, pandemic years included" }, "kind": "a statistical range, not company guidance; no view on the share price", "track": { "backtest": { "tests": 10, "hits": 6, "rate": 0.6, "method": "v4", "byYear": { "2013": [ 0, 1 ], "2014": [ 0, 1 ], "2017": [ 0, 1 ], "2019": [ 1, 1 ], "2020": [ 0, 1 ], "2021": [ 1, 1 ], "2022": [ 1, 1 ], "2023": [ 1, 1 ], "2024": [ 1, 1 ], "2025": [ 1, 1 ] }, "note": "hindsight: the same credibility-weighted range on the company's own past years. Years 2018-2023 were used to fit or tune the method, so only 2025 outcomes are fully out of sample." }, "registry": { "logged": "2026-09-27T21:32:54.648Z", "hash": "9195dc12be8163ef", "status": "open" }, "scorecard": "https://www.pops4.com/boards/scorecard" } }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0000914475.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=914475" }, "speedCash": { "fiscalYear": 2025, "cashConversion": 0.2736, "growth3y": 0.2432, "volatility": 0.0327, "paysDividend": false, "raisedDividend": false, "equityRatio": 0.7024, "quadrant": { "code": "fs", "label": "Fast and steady", "plain": "growing faster than its size class, with steadier revenue" }, "compass": { "code": "later", "inside": "Turns 27.4% of revenue into operating cash; revenue growing 24.3% a year over three years; no common dividend.", "outside": "Among $1B-10B companies: 78th percentile for cash, 91st for growth.", "emoji": "🌱", "label": "Cash cow later", "plain": "growing fast, and already turning revenue into cash" }, "band": "$1B-10B", "cashPctInClass": 78, "growthPctInClass": 91, "source": "SEC XBRL frames, the company’s own audited figures; quadrant split at the median of its size class" }, "harbor": { "signs": [], "rule": "Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider.", "level": 0, "name": "New ship", "plain": "no warning signs" }, "cashFlow": { "fiscalYearEnd": "2025-12-31", "operating": 782700000, "investing": -264400000, "financing": -38300000, "capitalSpending": 34000000, "free": 748700000, "trend": [ { "fiscalYearEnd": "2021-12-31", "operating": 256500000, "free": 233100000 }, { "fiscalYearEnd": "2022-12-31", "operating": 339400000, "free": 322900000 }, { "fiscalYearEnd": "2023-12-31", "operating": 389900000, "free": 361600000 }, { "fiscalYearEnd": "2024-12-31", "operating": 595400000, "free": 557200000 }, { "fiscalYearEnd": "2025-12-31", "operating": 782700000, "free": 748700000 } ], "note": "Annual, as filed in 10-K cash flow statements; negative investing/financing = cash going out (capital spending, buybacks, dividends, debt repaid)." }, "investments": { "fiscalYearEnd": "2025-12-31", "cash": 713000000, "shortTerm": 767400000, "longTerm": 1063000000, "equityHoldings": null, "totalAssets": 4631500000, "ladder": null, "currentRatio": 3.39, "unrealizedGain": null, "unrealizedLoss": null, "note": "Balance-sheet cash and investment securities at fiscal year end, as filed; short-term = due or saleable within a year. Insurers and banks hold most of their book here." } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same range method applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so.", "healthWatch": "Distress-type events the company filed in the last 12 months (late-filing notices; 8-K items 1.03, 3.01, 2.04, 4.02, 4.01, 2.05, 2.06, 1.05, 5.02), each with its count and newest filing. Display only: they do not change the range or its receipt." }, "speedCash": { "fiscalYear": 2025, "cashConversion": 0.2736, "growth3y": 0.2432, "volatility": 0.0327, "paysDividend": false, "raisedDividend": false, "equityRatio": 0.7024, "quadrant": { "code": "fs", "label": "Fast and steady", "plain": "growing faster than its size class, with steadier revenue" }, "compass": { "code": "later", "inside": "Turns 27.4% of revenue into operating cash; revenue growing 24.3% a year over three years; no common dividend.", "outside": "Among $1B-10B companies: 78th percentile for cash, 91st for growth.", "emoji": "🌱", "label": "Cash cow later", "plain": "growing fast, and already turning revenue into cash" }, "band": "$1B-10B", "cashPctInClass": 78, "growthPctInClass": 91, "source": "SEC XBRL frames, the company’s own audited figures; quadrant split at the median of its size class" }, "harbor": { "signs": [], "rule": "Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider.", "level": 0, "name": "New ship", "plain": "no warning signs" }, "cashFlow": { "fiscalYearEnd": "2025-12-31", "operating": 782700000, "investing": -264400000, "financing": -38300000, "capitalSpending": 34000000, "free": 748700000, "trend": [ { "fiscalYearEnd": "2021-12-31", "operating": 256500000, "free": 233100000 }, { "fiscalYearEnd": "2022-12-31", "operating": 339400000, "free": 322900000 }, { "fiscalYearEnd": "2023-12-31", "operating": 389900000, "free": 361600000 }, { "fiscalYearEnd": "2024-12-31", "operating": 595400000, "free": 557200000 }, { "fiscalYearEnd": "2025-12-31", "operating": 782700000, "free": 748700000 } ], "note": "Annual, as filed in 10-K cash flow statements; negative investing/financing = cash going out (capital spending, buybacks, dividends, debt repaid)." }, "investments": { "fiscalYearEnd": "2025-12-31", "cash": 713000000, "shortTerm": 767400000, "longTerm": 1063000000, "equityHoldings": null, "totalAssets": 4631500000, "ladder": null, "currentRatio": 3.39, "unrealizedGain": null, "unrealizedLoss": null, "note": "Balance-sheet cash and investment securities at fiscal year end, as filed; short-term = due or saleable within a year. Insurers and banks hold most of their book here." } }